Deciphera Pharmaceuticals, Inc. to Participate in Upcoming Investor Conferences

Rhea-AI Summary

Deciphera Pharmaceuticals will participate in multiple investor conferences in November 2022. Key dates include:

• Stifel Healthcare Conference on November 15 at 10:55 AM ET in New York, NY
• Jefferies London Healthcare Conference on November 17 at 8:30 AM ET in London
• Piper Sandler 34th Annual Healthcare Conference on November 29 at 4:00 PM ET in New York, NY

Live webcasts will be accessible via the company’s investor website, with replays available for 90 days.

Deciphera is focused on developing innovative cancer therapies, including QINLOCK®, approved in multiple countries.

WALTHAM, Mass.--(BUSINESS WIRE)-- Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) today announced that members of the management team will participate in fireside chats at the following investor conferences:

• Stifel Healthcare Conference on Tuesday, November 15, 2022 at 10:55 AM ET in New York, NY
• Jefferies London Healthcare Conference on Thursday, November 17, 2022 at 8:30 AM ET / 1:30 PM GMT in London, United Kingdom
• Piper Sandler 34th Annual Healthcare Conference on Tuesday, November 29, 2022 at 4:00 PM ET in New York, NY

Live webcasts will be available on the “Events and Presentations” page in the “Investors” section of the Company’s website at https://investors.deciphera.com/events-presentations. All webcast replays will be archived on the Company’s website for 90 days following the presentation.

About Deciphera Pharmaceuticals

Deciphera is a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer. We are leveraging our proprietary switch-control kinase inhibitor platform and deep expertise in kinase biology to develop a broad portfolio of innovative medicines. In addition to advancing multiple product candidates from our platform in clinical studies, QINLOCK® is Deciphera’s switch control inhibitor for the treatment of fourth-line GIST. QINLOCK is approved in Australia, Canada, China, the European Union, Hong Kong, Switzerland, Taiwan, the United Kingdom, and the United States. For more information, visit www.deciphera.com and follow us on LinkedIn and Twitter (@Deciphera).

View source version on businesswire.com: https://www.businesswire.com/news/home/20221108005236/en/

Investor Relations:

Maghan Meyers

Argot Partners

Deciphera@argotpartners.com

212-600-1902

Media:

David Rosen

Argot Partners

david.rosen@argotpartners.com

212-600-1902

Source: Deciphera Pharmaceuticals, Inc.

FAQ

What investor conferences will Deciphera Pharmaceuticals participate in November 2022?

Deciphera Pharmaceuticals will participate in the Stifel Healthcare Conference on November 15, Jefferies London Healthcare Conference on November 17, and Piper Sandler Healthcare Conference on November 29.

When will Deciphera Pharmaceuticals present at the Stifel Healthcare Conference?

Deciphera will present at the Stifel Healthcare Conference on November 15, 2022, at 10:55 AM ET.

Where can I watch Deciphera Pharmaceuticals' conference presentations?

Live webcasts of Deciphera Pharmaceuticals' presentations will be available on their 'Events and Presentations' web page.

What is QINLOCK and where is it approved?

QINLOCK is Deciphera's switch control inhibitor for treating fourth-line GIST, approved in countries including the United States, Canada, and the European Union.

What is Deciphera Pharmaceuticals' focus in biopharmaceuticals?

Deciphera Pharmaceuticals focuses on discovering and developing new medicines for cancer treatment using innovative technologies.